205 related articles for article (PubMed ID: 9514177)
21. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
22. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
[TBL] [Abstract][Full Text] [Related]
23. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
24. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study).
Hong TT; Huang J; Driscoll E; Lucchesi BR
J Cardiovasc Pharmacol; 2005 Oct; 46(4):526-33. PubMed ID: 16160608
[TBL] [Abstract][Full Text] [Related]
25. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Wåhlander K; Lapidus L; Olsson CG; Thuresson A; Eriksson UG; Larson G; Eriksson H
Thromb Res; 2002 Aug; 107(3-4):93-9. PubMed ID: 12431473
[TBL] [Abstract][Full Text] [Related]
27. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
28. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
29. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
[TBL] [Abstract][Full Text] [Related]
30. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
[TBL] [Abstract][Full Text] [Related]
31. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Morishima Y; Kamisato C; Honda Y
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
[TBL] [Abstract][Full Text] [Related]
33. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Koestenberger M; Cvirn G; Gallistl S; Muntean W
Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
[TBL] [Abstract][Full Text] [Related]
34. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
[TBL] [Abstract][Full Text] [Related]
36. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor.
Haskel EJ; Torr SR; Day KC; Palmier MO; Wun TC; Sobel BE; Abendschein DR
Circulation; 1991 Aug; 84(2):821-7. PubMed ID: 1860224
[TBL] [Abstract][Full Text] [Related]
37. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
Rigel DF; Olson RW; Lappe RW
Circ Res; 1993 May; 72(5):1091-102. PubMed ID: 8477521
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
39. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Klement P; Carlsson S; Rak J; Liao P; Vlasin M; Stafford A; Johnston M; Weitz JI
J Thromb Haemost; 2003 Mar; 1(3):587-94. PubMed ID: 12871470
[TBL] [Abstract][Full Text] [Related]
40. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Boström SL; Hansson GF; Kjaer M; Sarich TC
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):457-62. PubMed ID: 12851531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
